All In MedTech

Device Trial Radar · NCT04004169

Closed-Loop Deep Brain Stimulation for Major Depression

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Depression

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jul 18, 2019

Primary completion

Jun 28, 2030

Study completion Jun 28, 2035

Sponsor

Lead sponsor
Andrew KrystalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 1, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry. One way to change brain function is using electrical stimulation to help alter the communication between groups of neurons in the brain. The purpose of this study is to test a personalized approach to brain stimulation as an intervention for depression. The study researchers will use a surgically implanted device to measure each individual's brain activity related to his/her depression. The researchers will then use small electrical impulses to alter that brain activity and measure whether these changes help reduce depression symptoms. This study is intended for patients with major depression whose symptoms have not been adequately treated with currently available therapies. The device used in this study is called the NeuroPace Responsive Neurostimulation (RNS) System. It is currently FDA approved to treat patients with epilepsy. The study will test whether personalized responsive neurostimulation can safely and effectively treat depression.

Conditions

  • Major Depressive Disorder

Interventions

  • Stimulation-ONDevice

    Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker

  • Stimulation-OFFDevice

    No neurostimulation from the NeuroPace RNS® System

  • Stimulation-ON Active ControlDevice

    Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in MADRS scoreTime frame: administered at baseline and every 2 weeks for the first 18 weeks of stage 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.